Edwards Lifesciences Intrinsic Value – Edwards Lifesciences Corp. Stock Slips 0.78% Despite Positive Trading Session
July 18, 2023
🌧️Trending News
Monday was a positive day for the stock market overall, but Edwards Lifesciences ($NYSE:EW) Corp. saw its shares slip 0.78% to $92.65. Edwards Lifesciences is a global medical technology company, specializing in the development, manufacturing, and distribution of innovative cardiovascular innovations for patient care. Their products are used for the treatment of structural heart disease and critical care and vascular diseases. The company has a strong portfolio of products, including heart valve therapies, coronary products, critical care products, and more.
Edwards Lifesciences has a strong presence in the healthcare industry, with a focus on providing solutions to improve patient outcomes. The company is well known for its commitment to innovation and quality of care, which is evident in its diverse portfolio of products. Despite the slight dip in its stock price on Monday, the company remains well positioned to succeed in the long-term.
Analysis – Edwards Lifesciences Intrinsic Value
GoodWhale conducts financial analysis of EDWARDS LIFESCIENCES to help investors make informed decisions. Our proprietary Valuation Line indicates that the intrinsic value of EDWARDS LIFESCIENCES share is around $104.1. This implies that the stock is currently undervalued, as it is now traded at $92.6, a fair price that is 11.0% lower than its intrinsic value. This could be a great opportunity for any investors looking for an upside potential in the near future. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Edwards Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 5.5k | 1.49k | 28.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Edwards Lifesciences. More…
| Operations | Investing | Financing |
| 1.22k | 252.3 | -1.58k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Edwards Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 8.65k | 2.59k | 9.86 |
Key Ratios Snapshot
Some of the financial key ratios for Edwards Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.1% | 11.1% | 32.3% |
| FCF Margin | ROE | ROA |
| 17.3% | 18.8% | 12.8% |
Peers
Edwards Lifesciences Corp is a global leader in the development of products and technologies to treat cardiovascular disease. The company’s products are used by healthcare professionals to treat patients suffering from cardiac and vascular diseases. Edwards Lifesciences Corp’s competitors include Implanet SA, Avra Medical Robotics Inc, and Paragon 28 Inc.
– Implanet SA ($OTCPK:IMPZY)
Implanet SA is an orthopedic company that manufactures and distributes medical devices. The company has a market cap of 3.76M as of 2022 and a Return on Equity of -114.56%. The company’s products are used in the treatment of conditions such as osteoarthritis, degenerative disc disease, and deformities of the spine and extremities.
– Avra Medical Robotics Inc ($OTCPK:AVMR)
Avra Medical Robotics Inc is a publicly traded company with a market capitalization of 239.1 thousand dollars as of 2022. The company focuses on the development and commercialization of robotic technologies for use in minimally invasive surgery. The company’s primary product is the Avra Surgical System, a surgical robotics platform that assists surgeons in performing tasks such as suturing, tissue manipulation, and vessel sealing. The company has received FDA clearance for the Avra Surgical System and has CE Mark approval for the European Union.
– Paragon 28 Inc ($NYSE:FNA)
Paragon 28 Inc is a publicly traded company with a market capitalization of 1.33 billion as of 2022. The company has a negative return on equity of 9.25%. Paragon 28 Inc is engaged in the business of providing turnkey engineering, procurement and construction services to the oil and gas industry.
Summary
On Monday, Edwards Lifesciences Corp. shares experienced a slight dip, closing at $92.65. Despite this drop, overall the stock market had a positive performance. Investors should consider this company’s positive outlook, as it has been on an upward trend for the past several months. With its solid earnings and consistent dividends, Edwards Lifesciences Corp. is an attractive option for those looking to invest in a reliable stock.
Its growing market share and strong financials make it a prime candidate for long-term investments. Analysts have recommended that investors buy the stock on dips and hold it for potential gains in the future.
